KarisBio is a biotechnology company developing next-generation cell and gene therapies based on induced pluripotent stem cell (iPSC) technology. We are the first in the world to initiate a clinical trial with iPSC-derived endothelial cells (iPSC-ECs), proving both commercialization potential and execution capability. With proprietary iPSC differentiation and manufacturing processes, GMP production facilities, and efficacy validation in diverse disease models, KarisBio has established itself as a comprehensive platform company supporting research, clinical development, and quality testing. Our iPSC pipeline initially targets cardiovascular diseases but extends to multiple therapeutic areas. We also provide customized cell manufacturing and supply services for both research-grade and GMP-grade needs.

iPSC-derived Endothelial Cells Therapy, Commercial Production and Supply of iPSC-based Cells, Preclinical Animal Model Development Services, Manufacturing and Distribution of Clinical-grade iPSCs, Cell Therapy CMO/CDMO Services, Advanced Combination Therapies (iPSC-EC + Biomaterials), Direct Reprogramming-based Cell Therapeutics, Vascularized Cardiac Organoids